唑来膦酸联合吉西他滨治疗非小细胞肺癌疗效观察

目的 观察唑来膦酸联合吉西他滨治疗非小细胞肺癌(NSCLC)的临床效果.方法 选择上海市浦东新区肺科医院2015年1月至2016年3月收治的92例预计生存期大于3个月的NSCLC患者,采用随机数表法分为两组,每组46例,对照组患者接受标准一线化疗GP方案,观察组患者在此基础上给予唑来膦酸治疗,3周为一个周期,共治疗3个周期.治疗前、治疗3个周期后评价患者疼痛缓解情况、健康状况、骨转移灶疗效及不良反应.结果 治疗后观察组和对照组患者的NRS评分分别为(3.32±0.84)分和(4.92±1.13)分,均明显低于各组治疗前的(6.03±1.26)分和(6.12±1.54)分,且观察组低于对照组,差异均有统计学意义(P<0.05);治疗后观察组和对照组患者的Karnofsky评分分别为(71.29±12.47)分和(65.82±11.29)分,均明显高于各组治疗前的(54.07±9.46)分和(53.22±10.84)分,且观察组高于对照组,差异均有统计学意义(P<0.05);观察组患者的治疗总有效率为60.87%,明显高于对照组的26.09%,差异有统计学意义(P<0.05);两组患者的不良反应比较差异无统计学意义(P>0.05).结论 唑来膦酸与吉西他滨联合应用可能产生协同作用,治疗NSCLC疗效显著,安全性好.

Collaborative action research of azole phosphonic acid and gemcitabine for the treatment of non-small cell lung cancer.

Objective To observe the curative effect of azole phosphonic acid combined with gemcitabine in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 92 cases of NSCLC patients with an expect-ed survival of more than 3 months, who admitted to the Pulmonary Hospital of Pudong New Area from January 2015 to March 2016, were selected and divided into the two groups by using random number table, with 46 cases in each group. The control group patients received standard first-line chemotherapy GP, and the observation group was treated with azole phosphonic acid on the basis of the control group's treatment. Three weeks for one treatment course, all the patients were treated for three courses. The pain relief, health, bone metastases curative effect and adverse reactions of the pa-tients before and after the three courses were evaluated. Results After the treatment, the numeric rating scale (NRS) scores of the observation group and the control group were respectively (3.32±0.84) and (4.92±1.13), which were signifi-cantly lower than (6.03 ± 1.26) and (6.12 ± 1.54) before the treatment;After the treatment, the NRS score of the observa-tion group was significantly lower than the control group (P<0.05). After the treatment, the Karnofsky scores of the ob-servation group and the control group were respectively (71.29±12.47) and (65.82±11.29), which were significantly high-er than (54.07 ± 9.46) and (53.22 ± 10.84) of before the treatment, and the observation group is significantly higher than the control group (P<0.05). The total effective rate of treatment in the observation group was 60.87%, which was signifi-cantly higher than 26.09%in the control group (P<0.05). There was no significant difference between the two groups in adverse reactions (P>0.05). Conclusion The combined application of azole phosphonic acid and gemcitabine may have significant synergistic effect on the treatment of NSCLC with obvious therapeutic effect and good safety.